TherapeuticsMD, Inc.

Historical 13F Holders

Symbol
TXMD
CUSIP
88338N206
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 88338N206 since 12/18/2024, newest first.

Filer % of Class Filed
Baselake Partners, LP 13G/A Amendment 1
6.8% 8/5/2026
Event 6/30/2026
Baselake Partners, LP 13G
5.2% 4/6/2026
Event 3/30/2026
Clearline Capital LP 13G
5.5% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 71.0 $144.00
2026 Q2 47 3.67 M $9.10 M
2026 Q1 51 3.93 M $7.94 M
2025 Q4 47 3.39 M $5.52 M
2025 Q3 47 3.30 M $3.54 M
2025 Q2 46 3.26 M $3.78 M
2025 Q1 45 3.34 M $3.09 M
2024 Q4 44 3.53 M $3.03 M
2024 Q3 41 3.38 M $5.61 M
2024 Q2 43 3.54 M $5.70 M
2024 Q1 49 3.64 M $8.34 M
2023 Q4 45 3.38 M $7.61 M
2023 Q3 40 2.99 M $9.32 M
2023 Q2 47 3.03 M $12.5 M
2023 Q1 46 3.12 M $11.7 M
2022 Q4 53 3.50 M $19.6 M
2022 Q3 51 2.07 M $13.8 M
2022 Q2 62 2.07 M $20.2 M
2022 Q1 2 10.8 k $4.10 k
2021 Q4 1 10.0 k $3.56 k